Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare

NEW YORK–(BUSINESS WIRE)– Cellectis
(Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused
on developing immunotherapies based on gene edited CAR T-cells (UCART),
today announced that the Company has won EuropaBio’s 2016
Most Innovative European Biotech SME Award for the healthcare
category. The Awards program represents a unique annual initiative (now
in its seventh year) that recognizes innovative biotech small- and
medium-sized enterprises (SMEs) in Europe and the crucial role that they
play in answering some of society’s greatest challenges through
biotechnology.

Cellectis’ selection was based on the Company’s contribution to and
impact on the global healthcare and life sciences industries via its
development and therapeutic application of allogeneic CAR T-cell
immunotherapies that target cancer. In this process, T-cells from
healthy donors are genetically edited with Cellectis’ TALEN®
technology to seek and destroy cancer cells.

“It is an honor for Cellectis to receive this award for our pioneering
gene editing technology and immunotherapies, which will bring
cutting-edge cancer treatment globally to patients who have high unmet
medical needs,” said Dr. André Choulika, Chairman and Chief Executive
Officer, Cellectis. “As we work hard to bring our product candidates to
patients, programs like the EuropaBio SME Awards create an environment
of strong support and a platform for discussing continuing innovation
for bioscience companies across the board.”

“Raising the profile for innovative biotech companies in Europe, both
collectively and individually, offers the opportunity to demonstrate the
enormous potential of our entrepreneurs in this sector,” added Tom
Saylor, Chairman of the EuropaBio SME Platform. “Finalists enjoy the
chance to showcase their capabilities to potential partners, investors
and collaborators, and past finalists have shown that this award can
provide a platform for access to resources and exposure that can
contribute to ongoing success in the future.”

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN^® products
and meganucleases and pioneering electroporation PulseAgile technology –
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it.
TALEN® is a registered
trademark owned by the Cellectis Group.

About EuropaBio’s European Biotech SME Awards 2016

EuropaBio, the European Association for Bioindustries, invited SMEs
across Europe to apply for the 7th edition of the Most Innovative
European Biotech SME Award. Depending on their field of activity, SMEs
could apply in 3 categories: healthcare, agricultural or industrial
biotech. Three companies were shortlisted in each category by a jury or
biotech experts, with the winners celebrated during a landmark event for
SMEs held in the course of European Biotech Week in late September.

The members of EuropaBio are involved in research, development, testing,
manufacturing and commercialization of biotech products and processes in
human and animal healthcare, diagnostics, bioinformatics, chemicals,
crop protection, agriculture, food and environmental products and
services. EuropaBio also counts a number of National Biotech
Associations in its membership who in turn represent more than 1800
biotech SMEs. EuropaBio’s SME Platform focuses its activities on
highlighting challenges and financial constraints that biotech SMEs
face, and developing policy recommendations to optimise EU and member
state funding instruments for biotech SMEs. The SME Platform brings
together CEOs of SMEs, National Biotech Associations, Venture
Capitalists and private banks, European financial institutions,
representatives from the EC, and other interested stakeholders.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160927006684/en/